Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML)

被引：0

作者：

Garcia-Manero, G.

Yang, A. S.

Klimek, V.

Luger, S.

Newsome, W. M.

Berman, N.

Patterson, T.

Maroun, C.

Li, Z.

Ward, R.

Martell, R.

机构：

[1] UT MD Anderson Canc Ctr, Houston, TX USA

[2] Norris Cromprenhens Canc Ctr, Los Angeles, CA USA

[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[4] Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA

[5] MethylGene, Montreal, PQ, Canada

[6] Pharmion, San Francisco, CA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7062

引用

页数：1